NETest Supporting Data

The NETest is a novel blood-based laboratory developed test (LDT), a molecular diagnostic, that provides sensitive and specific information with respect to a neuroendocrine tumor status. The test is unique in that it uses 51 neuroendocrine tumor gene transcripts and novel state-of-the-art molecular biomarker analyses developed by Wren scientists. This allows us to monitor neuroendocrine tumor gene activity levels.

The NETest is:

  1. A circulating fingerprint developed from analyses of neuroendocrine tumor transcriptomes (1-3).
  2. A multianalyte analytic algorithm (MAAA) that captures the hallmarks of neuroendocrine tumor biology (3,4).
  3. Highly sensitive and specific for detecting neuroendocrine tumor disease (3-6).
  4. More sensitive than single analyte ELISAs for detecting disease (4-7).
  5. More sensitive than measuring chromogranin A for evaluating neuroendocrine tumor disease status (4-7).
  6. Unaffected by concomitant PPI use (6-7).

Clinically, NETest scores:

  1. Accurately diagnose neuroendocrine tumor disease (4-7).
  2. Provides biochemical assessment of the extent of surgical cytoreduction (8).
  3. Accurately defines stable and progressive disease (9,10).
  4. Identifies stable and progressive clinical disease activity during somatostatin analog therapy treatment (9,10).
  5. Can identify biochemical evidence of neuroendocrine tumor disease recurrence prior to topographic (CT/MRI) or functional imaging (68Gallium PET or Octreoscan) (10-11).

A combination of grade and 8 NETest genes (PPQ - PRRT predictive quotient) can predict the efficacy of peptide receptor radiotherapy (PRRT) and monitor tumor response (11).

References (Click on title for .PDF)